MDT
Medtronic plc
Set alert
- YTD
- +0.50%
- 1 year
- +6.12%
- Open
- 98.00
- Prev close
- 97.11
- Mkt cap
- 123.49B
- Vol
- 8.68M
- Avg vol
- 16.43M
- EPS
- 4.07
- P/E
- 23.72
- Div yield
- 2.97%
More statistics
- Low
- 96.46
- High
- 98.09
- Forward P/E
- 15.11
- Beta
- 0.57
- Short ratio
- 4.63
- Inst. own
- 88.78%
- Dividend
- 2.88
- Ex-div date
- Sep 24, 2026
- Earnings
- Nov 17, 2026
- 50-d avg
- 91.62
- 200-d avg
- 88.17
- 1y target
- 104.62
Key statistics
- Market cap
- 123.79B
- Enterprise value
- 144.17B
- Trailing P/E
- 23.78
- Forward P/E
- 15.11
- PEG ratio
- 1.74
- Price / sales
- 3.30
- Price / book
- 2.47
- EPS (TTM)
- 4.07
- Beta
- 0.57
- Dividend yield
- 2.97%
- Payout ratio
- 70.02%
- Profit margin
- 13.93%
- Revenue (TTM)
- 37.54B
- Revenue growth
- 13.70%
- Free cash flow
- 5.41B
- Total cash
- 8.82B
- Total debt
- 28.15B
- Return on equity
- 10.65%
- Shares outstanding
- 1.28B
- Short % of float
- 10.89%
- 50-day average
- 91.62
- 200-day average
- 88.17
Analyst view
Consensus: buy
- Target (low)
- 85.00
- Target (mean)
- 104.62
- Target (high)
- 121.00
- Strong buy3
- Buy17
- Hold10
- Sell0
- Strong sell0
Next earnings
Nov 17, 2026
Expected Nov 17, 2026. Consensus EPS estimate 1.33.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 17, 2026 | Oct 31, 2026 | 1.33 | — | — | — |
| Sep 1, 2026 | Jul 31, 2026 | 1.39 | 1.45 | +0.06 | +4.32% |
| Jun 3, 2026 | Apr 24, 2026 | 1.54 | 1.55 | +0.01 | +0.65% |
| Feb 17, 2026 | Jan 23, 2026 | 1.34 | 1.36 | +0.02 | +1.49% |
| Nov 18, 2025 | Oct 24, 2025 | 1.31 | 1.36 | +0.05 | +3.82% |
| Aug 19, 2025 | Jul 25, 2025 | 1.23 | 1.26 | +0.03 | +2.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | BTIG | main | Buy | Buy |
| Oct 7, 2026 | Barclays | init | — | Equal-Weight |
| Sep 30, 2026 | TD Cowen | reit | Buy | Buy |
| Sep 3, 2026 | UBS | main | Buy | Buy |
| Sep 2, 2026 | Truist Securities | reit | Hold | Hold |
| Sep 2, 2026 | Wells Fargo | main | Overweight | Overweight |
About Medtronic plc
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Ireland
- Website
- medtronic.com
News
- Why the Market Dipped But Medtronic (MDT) Gained Today
- Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
- American Century Equity Income Fund Q3 2026 Portfolio Activity
- Medtronic: Broader Growth, Attractive Valuation
- Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
- Medtronic Quietly Raised Its Dividend Again. Is It a Buy for Income Investors?
- A Look at Medtronic PLC (MDT) After 3.8% Gain -- GF Value $101.17 vs Price $96.59
- Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
- Medtronic Announces Real-World Registry Results For Its Affera Mapping And Ablation System With The Sphere-9 Catheter And The PulseSelect Pulsed Field Ablation System; Analyses Report Strong Safety And Procedural Outcomes Across Atrial And Ventricular Arrhythmias
- Medtronic announces positive results from real-world registries for the Sphere-9™ catheter and PulseSelect™ PFA System at APHRS 2026
Your note
Sign in to keep a note on MDT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARNOLD CRAIG | Director | Stock Award(Grant) | Apr 26, 2026 | 42,185 |
| CORONA GARY LOUIS | Chief Financial Officer | Stock Award(Grant) | Jan 20, 2025 | 44,255 |
| HOGAN RANDALL J III | Director | Stock Award(Grant) | Apr 26, 2026 | 48,998 |
| KIIL HARRY SKIP | Officer | Sale | Sep 15, 2026 | 42,186 |
| MARINARO MICHAEL | Officer | Stock Award(Grant) | Aug 2, 2026 | 117,420 |
| MARTHA GEOFFREY S | Chief Executive Officer | Stock Award(Grant) | Aug 2, 2026 | 327,866 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.91% | 114,020,787 | 11.03B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.55% | 83,816,735 | 8.11B | Jun 29, 2026 |
| State Street Corporation | 4.96% | 63,399,315 | 6.14B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.66% | 34,059,967 | 3.30B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.36% | 30,192,015 | 2.92B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 2.17% | 27,784,471 | 2.69B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.19% | 40,757,422 | 3.94B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.60% | 33,271,457 | 3.22B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 17,056,298 | 1.65B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 16,665,982 | 1.61B | Aug 30, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 15,820,582 | 1.53B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Value Index Fund | 0.96% | 12,221,643 | 1.18B | Jun 29, 2026 |